Episode 442: The ACTRIMS Forum (Pt 2) with Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Ozug скачать в хорошем качестве

Episode 442: The ACTRIMS Forum (Pt 2) with Dr. Jeffrey Cohen, Dr. Daniel Ontaneda, and Kristine Ozug

Welcome back to Part Two of our coverage of the 2026 ACTRIMS Forum. This week, we shift our focus to emerging therapies and clinical insights that are re-shaping the future of MS care. From the latest information on stem cell transplantation to evolving treatment strategies to the labels used to describe MS, we’re breaking down the complex science into the conversations that matter most to the MS community. Joining me to discuss one of the most significant presentations from the 2026 ACTRIMS Forum is Dr. Jeffrey Cohen, who opened the event with the Kenneth P. Johnson Memorial Lecture. Dr. Cohen’s lecture, "AHSCT: Current Status and Remaining Questions," tackled a topic of massive interest to both clinicians and the MS community: Autologous Hematopoietic Stem Cell Transplantation (AHSCT). Often described as "resetting" the immune system, AHSCT is a complex and life-changing procedure that continues to evolve. In our conversation, Dr. Cohen delves deeper into his lecture, discussing transplant efficacy, the best candidates for AHSCT, the optimal time to consider AHSCT, and how people living with MS may qualify to participate in a clinical trial comparing the benefits of AHSCT with those of high-efficacy disease-modifying therapies. Joining me for a deep dive into the future of MS care is Dr. Daniel Ontaneda. Our wide-ranging conversation explores the cutting edge of clinical practice and research, including the "early vs aggressive" treatment debate, how incorporating new imaging biomarkers will lead to faster, more reliable, and more accurate MS diagnoses, and whether the current disease classifications still serve the best interests of patient care. While MS research conferences like the ACTRIMS Forum are never short on world-class expert opinions and groundbreaking data, one perspective is often missing from the room: the voice of someone living with the disease. That’s why I was so glad to have Kristine Werner Ozug, a valued member of the RealTalk MS team, on the ground with me. As someone living with MS, Kristine brings a vital lens to these scientific sessions. After the final gavel fell, I sat down with her to get her "patient-first" perspective on the research that mattered most to her and what she’s taking away from this year’s Forum. Are you ready for RealTalk MS??!